SCHEMBL12409485

SCHEMBL12409485

Cc1cnc(NCc2ccc(S(N)(=O)=O)cc2)c2ncc(-c3ccc(O)cc3F)n12

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA1 P00915 11/20 0.41
CA2 P00918 11/20 0.41
CA9 Q16790 7/20 0.38
KDM4E B2RXH2 1/20 0.38
NPC1 O15118 1/20 0.38
MAPT P10636 1/20 0.38
CA7 P43166 2/20 0.37
CA13 Q8N1Q1 2/20 0.37
NTRK1 P04629 1/20 0.37
NTRK3 Q16288 1/20 0.37
NTRK2 Q16620 1/20 0.37
CA12 O43570 1/20 0.36
ALOX5 P09917 1/20 0.36
LTB4R Q15722 1/20 0.36
PTGS2 P35354 1/20 0.36
STK17B O94768 1/20 0.36
CSF1R P07333 1/20 0.36
IKBKE Q14164 1/20 0.36
AAK1 Q2M2I8 1/20 0.36
LRRK2 Q5S007 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2177585 0.85 CA1 (0.48) CA1CA2CA9KDM4ENPC1
SCHEMBL12409483 0.85 PI4KB (0.44) CA1CA2CA9KDM4ENPC1
SCHEMBL2181407 0.83 CA1 (0.42) CA1CA2CA9KDM4ENPC1
SCHEMBL12409491 0.82 CA1 (0.40) CA1CA2CA9KDM4ENPC1
SCHEMBL12409486 0.81 CA1 (0.39) CA1CA2CA9KDM4ENPC1
SCHEMBL12409327 0.78 FYN (0.47) CA1CA2CA9CA7CA13
SCHEMBL2180092 0.77 KDM4E (0.45) CA1CA2CA9KDM4ENPC1
SCHEMBL12409489 0.76 NTRK1 (0.43) CA1CA2NTRK1NTRK3NTRK2
SCHEMBL12409487 0.76 PTGS2 (0.45) PTGS2PI4KB
SCHEMBL12409456 0.76 PI4KB (0.57) CA1CA2CA9KDM4ENPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8362018-B2 Substituted imidazo[1,2-a]pyrazine compounds useful for the treatment of viral infections BIOFOCUS DPI, LTD. (GB) 2013-01-29 US disclosed
US-8362018-B2 Substituted imidazo[1,2-a]pyrazine compounds useful for the treatment of viral infections BIOFOCUS DPI, LTD. (GB) 2013-01-29 US disclosed
US-20110166147-A1 IMIDAZOPYRAZINE COMPOUNDS BIOFOCUS DPI, LTD. (GB) 2011-07-07 US disclosed
US-20110166147-A1 IMIDAZOPYRAZINE COMPOUNDS BIOFOCUS DPI, LTD. (GB) 2011-07-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110166147-A1 IMIDAZOPYRAZINE COMPOUNDS CYP3A5, HAVCR2, CYP3A43 CA1 4484/4885CA2 4053/4885CA9 3952/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.